Drug intelligence / Profile preview

propofol + midazolam + fentanyl

Development stage: Unknown
Lead developer: AkzoNobel
Modality: Small Molecules
Administration: Intravenous

Overview

A combination of three medications used for procedural sedation and analgesia. This regimen combines propofol (a short-acting intravenous anesthetic), midazolam (a benzodiazepine sedative), and fentanyl (an opioid analgesic) to provide effective sedation, amnesia, and pain control during medical procedures. The combination leverages the complementary effects of these medications to achieve desired sedation levels while potentially allowing for lower doses of each individual component.

Other names: Propofol, Midazolam, and Fentanylpropofol + midazolam + fentanyl-Montefiore Medical Center-anesthesia

Targets

GABRR (GABA-A receptor subunit rho)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on propofol + midazolam + fentanyl.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on propofol + midazolam + fentanyl.

Explore the full profile